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Objectives
To perform a comparison and external validation of three
models predicting biochemical recurrence (BCR) and three
models predicting prostate cancer (PCa)-speciﬁc mortality
(PCSM) in a screening setting, i.e. patients with screening-
detected PCa (S-PCa) and in those with clinically detected
PCa (C-PCa).
Subjects and Methods
We retrospectively evaluated 795 men with S-PCa, from the
European Randomized Study of Screening for Prostate
Cancer, Rotterdam, and 1123 men with C-PCa initially
treated with RP. The discriminative ability of the models was
assessed according to the area under the curve (AUC) of the
receiver-operating characteristic, and calibration was assessed
graphically using calibration plots.
Results
The median (interquartile range [IQR]) follow-up for the S-
PCa group was 10.4 (6.8–14.3) years and for the C-PCa group
it was 8.8 (4.8–12.9) years. A total of 123 men with S-PCa
(15%) and 389 men with C-PCa (35%) experienced BCR. Of
the men with S-PCa and BCR, 24 (20%) died from PCa and 29
(23%) died from other causes. Of the men with C-PCa and
BCR, 68 (17%) died from PCa and 105 (27%) died from other
causes. The discrimination of the models predicting BCR or
PCSM was higher for men with S-PCa (AUC: BCR 0.77–0.84,
PCSM 0.60–0.77) than for the men with C-PCa (AUC: BCR
0.75–0.79, PCSM 0.51–0.68) as a result of the similar patient
characteristics of the men with S-PCa in the present study and
those of the cohorts used to develop these models. The risk of
BCR was typically overestimated, while the risk of PCSM was
typically underestimated.
Conclusion
Prediction models for BCR showed good discrimination and
reasonable calibration for both men with S-PCa and men
with C-PCa, and even better discrimination for men with S-
PCa. For PCSM, the evaluated models are not applicable in
both settings of this Dutch cohort as a result of substantial
miscalibration. This warrants caution when using these
models to communicate future risks in other clinical settings.
Keywords
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Introduction
Radical prostatectomy (RP) is a surgical treatment used for
localized prostate cancer (PCa), with overall high disease-
speciﬁc survival rates. It has been demonstrated that the 8-
year disease-speciﬁc survival for patients with pathological
Gleason score of ≥4 + 4 is > 80% [1,2]. RP is considered
successful if the PSA level after surgery drops to < 0.1 ng/mL.
In 10–20% of patients, PSA level will increase again within a
median period of 10 years after the RP procedure [3,4]. This
biochemical recurrence (BCR) is deﬁned as two successive
PSA levels ≥0.2 ng/mL and can eventually lead to PCa-
speciﬁc mortality (PCSM) in 2.5–17% of patients [3,5].
As such, early detection of BCR is important for management
of the disease [6]. To aid in clinical decision-making,
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multivariable prediction models have been developed to
provide the individual probability of BCR after RP, or PCSM
following BCR after RP, estimated on the basis of patient and
tumour characteristics. The estimates of these models are
often included in decision-making without sufﬁcient
knowledge of external validity, which potentially could lead to
erroneous individual risk assessments, thereby threatening
adequate decision-making regarding, for example, initiation of
salvage treatment.
We identiﬁed six prediction models, three of which were for
predicting BCR after RP: the model by Walz et al. [7] (2-year
BCR); the CAPRA nomogram by Cooperberg et al. [8] (5-
year BCR); and the Memorial Sloan-Kettering Cancer Center
(MSKCC) nomogram (5-year BCR; http://www.mskcc.org/ca
ncer-care/adult/prostate/prediction-tools; updated on 4
October 2018). The remaining three models were for
predicting PCSM following BCR after RP: models by
Dell’Oglio et al. [9] (5-year PCSM); Brockman et al. [10] (15-
year PCSM); and Eggener et al. [11] (15-year PCSM). All
cohorts underlying these models consisted of referral-based
patients. It was previously reported by Loeb et al. [3] that
patients with screening-detected PCa (S-PCa) had better
progression-free survival compared to men with clinically
detected PCa (C-PCa) (i.e. PCa detected in clinical practice).
Although less prominent, this was also true for PCSM.
The aims of the present study were to assess the predictive
performance (discrimination and calibration) of the six
prediction models in a true population-based PSA-driven
screening setting, i.e. patients with S-PCa within the Dutch
part of European Randomized Study of Screening for Prostate
Cancer (ERSPC) [12], and to compare the performance of the
model in a cohort of men with C-PCa from the same region.
Subjects and Methods
The ERSPC is a randomized controlled trial which studies the
effect of PSA-based screening on PCa mortality.
Randomization of men in the Dutch arm of the study was
initiated in December 1993. The ERSPC study characteristics
have been described previously [12]. In short, in the Dutch
arm of ERSPC a total of 42 376 men were randomized to
either a screening arm or a control arm. In the screening
arm, men were re-screened every 4 years and received a PSA
test and TRUS-guided prostate biopsy if PSA was ≥ 3.0 ng/
mL. In the early years an abnormal DRE could trigger biopsy
if PSA was < 4.0 ng/mL. Screening was discontinued if the
patient was diagnosed with PCa or reached the age of
74 years. In the control arm, men received no active
screening; treatment was offered if the patient was diagnosed
with PCa after referral.
In addition to data on the men with C-PCa in the ERSPC
Rotterdam study, data were available from men with C-PCa
initially treated with RP in the Erasmus Medical Centre PCa
study database. These men were not randomized as part of
the ERSPC trial, but their PCa was clinically detected in the
same region of Rotterdam. For both patients with S-PCa and
C-PCa, treatment was carried out according to contemporary
clinical practice.
After RP, pathological T-stage, nodal stage, Gleason grade,
degree of extraprostatic extension, and surgical margins were
assessed based on TNM 1992 classiﬁcation. In addition, PSA
was regularly measured after RP, and events of disease
progression and death were recorded through semi-annual
chart review. Cause of death was assessed by either a Cause of
Death Committee according to a ﬁxed algorithm if men were
included in the ERSPC Rotterdam study [13] or was based on
chart review by experienced urologists if men were not
included in the ERPSC Rotterdam study. For the BCR
prediction models, the aggregated patient criteria of the cohorts
of the studies in which the models were developed (i.e. the
development cohorts) comprised absence of neoadjuvant and
adjuvant therapy. For the PCSM prediction models, the
aggregated patient criteria of the original cohorts comprised
presence of BCR, and men with or without adjuvant therapy
were included. For all prediction models, men were excluded if
they had pathological T0 stage, had unknown surgery data, had
an unﬁnished surgery, had a diagnosis of PCa prior to
randomization or had undergone cystectomy.
Statistical Analyses
The probability of experiencing BCR or PCSM was calculated
using the required information for the prediction model
under study (Table 1 and Table S1). Comparison was
performed on the basis of discrimination and calibration.
Discrimination refers to the ability of a prediction model to
discriminate between patients with and without the event of
interest and was quantiﬁed using the time-dependent area
under the of the curve (AUC) of the receiver-operating
characteristic, with nearest-neighbour estimation [14,15].
Calibration refers to the agreement between predicted
probabilities and observed probabilities and was quantiﬁed
using the calibration slope. Ideally, the calibration slope is
equal to one. If the calibration slope is more than one, there
will be underestimation of the predicted risk. If the
calibration slope is less than one, there will be overestimation
of the predicted risk. For the calibration plots, patients were
divided into quintiles based on predicted event probability.
The average predicted event probability of each subset of
quintiles was plotted against the Kaplan–Meier event
probability of each corresponding subset of quintiles [16].
For the models predicting BCR, patients without progression
were censored at the last recorded date of PSA measurement
[17]. All statistical analyses were performed using R version
3.5.1, survival analyses were conducted with R-package
survival [18], missing values were imputed ﬁve times with R-
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package mice [19], receiver-operating characteristic curves
were computed by R-package survivalROC [20], and
visualization of the plots was performed with R-package
ggplot2 [21].
Results
Biochemical Recurrence after Radical
Prostatectomy
For the models predicting BCR after RP, the patient cohorts
consisted of 795 men with S-PCa who underwent surgery
between January 1994 and June 2016 (median November
1999), and 1123 men with C-PCa who underwent surgery
between February 1977 and August 2016 (median February
2001; Fig. 1). The overall median (interquartile range [IQR])
age at time of RP of the men with S-PCa was 66 (62–69)
years and for men with C-PCa it was 64 (59–68) years
(Table 2). The median (IQR) preoperative PSA level for men
with S-PCa was 4.9 (3.6–7.7) ng/mL and for the men with C-
PCa it was 8.9 (5.7–14.7) ng/mL. A total of 184 men (23%)
in the S-PCa group and 535 men (47%) in the C-PCa group
had a pathological T-stage of ≥T3. The overall median (IQR)
follow-up time for men with S-PCa was 10.4 (6.8–14.3) years
and for men with C-PCa it was 8.8 (4.8–12.9) years. A total
of 123 men with S-PCa (15%) and 389 men with C-PCa
(35%) experienced BCR. The overall median (IQR) age at the
Table 1 Overview of the included predictors per study for progression or prostate cancer-speciﬁc mortality in the prediction model
Age at
diagnosis
Age at
BCR
Time to
BCR
PSA for
RP
PSA
after RP
pGS pT pN EPE SM SVI RT HT
BCR
Walz et al. [7] + + + + + +
Cooperberg et al. [8] + + + + + +
MSKCC updated on 4
October 2018
+ + + + +
PCSM
Dell'Oglio et al. [9] + + + + + + + +
Brockman et al. [10] + + + + + + + +
Eggener et al. [11] + + + + + + +
BCR, biochemical recurrence; ECE, extraprostatic extension; HT, hormone therapy; MSKCC, Memorial Sloan-Kettering Cancer Center; OC, organ-conﬁned; PCSM, prostate cancer-
speciﬁc mortality; pGS, pathological Gleason score; pM, pathological M-stage; pN, pathological N-stage; pT, pathological T-stage; RT, radiotherapy; SM, surgical margins; SVI,
seminal vesicle invasion.
Exclusion(n = 122):
Patient selection
Screening-detected PCa
(n = 917)
(n = 795) (n = 1123)
Inclusion Inclusion
(n = 1242)
Clinically detected PCa
Prediction models for BCR
- Scheduled but not performed (n = 40)
- Cystectomy (n = 1)
- Unknown surgery data (n = 1)
- pTO (n = 9)
- No follow-up data (n = 3)
- Adjuvant radiotherapy (n = 11)
- Adjuvant hormonal medication (n = 2)
- Initial treated with radiotherapy (n = I)
- Initial treated with watchfull waiting (n = 53)
- Initial treated with hormonal therapy (n = 1)
Exclusion (n = 119):
- Scheduled but not performed (n = 26)
- pTO (n = 15)
- No follow-up data (n = 3)
- Adjuvant radiotherapy (n = 5)
- Adjuvant hormonal medication (n = 2)
- Initial treated with watchfull waiting (n = 56)
- Initial treated with hormonal therapy (n = 12)
Fig. 1 Flowchart of the patient inclusion process for the external validation of the models predicting biochemical recurrence (BCR) after radical
prostatectomy. PCa, prostate cancer.
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time of RP of the men who experienced BCR was 67 (63–69)
years for S-PCa group and 64 (59–68) for the C-PCa group.
There was no substantial difference in discrimination between the
models, but a higher AUC was found for men with S-PCa (AUC
range 0.77–0.84) vs men with C-PCa (AUC range 0.75–0.79;
Fig. S1). For the model by Cooperberg et al. [8], the calibration
slope was 0.79 for C-PCa and 1.003 for S-PCa, for the model by
Walz et al. [7] it was 0.70 for C-PCa and 0.92 for S-PCa, and for
the MSKCC model it was 0.25 for C-PCa and 0.66 for S-PCa. The
calibration of the models was in general more accurate for the
men with C-PCa: the degree of overestimation of the predicted
probabilities of experiencing BCR was higher for the men with S-
PCa (Fig. S2) as the calibration slope was < 45 degrees. The
calibration of the MKSCC model for both S-PCa and C-PCa is
shown in detail in Fig. S3.
Prostate Cancer-Speciﬁc Mortality Following
Biochemical Recurrence after Radical
Prostatectomy
A total of 123 men with S-PCa and 389 men with C-PCa
experienced BCR (Fig. 2). The median (IQR) time to BCR
after diagnosis was 3.3 (1.7–7.3) years for men with S-PCa
and 2.4 (1.0–5.1) years for men with C-PCa (Table 2). For
the men in both the S-PCa and C-PCa groups who
experienced BCR, about the same proportion of men died
from either PCa or other causes. To elaborate, of the men
with S-PCa who experienced BCR, 24 (20%) died from PCa
and 29 (24%) died from other causes. Of the men with C-
PCa who experienced BCR, 68 (17%) died from PCa and 105
(27%) died from other causes (Table 3). Among the men who
died from PCa, the median (IQR) follow-up in the S-PCa
group was 7.2 (4.9–11.8) years, and in the C-PCa group it
was 8.9 (6.3–11.2) years.
The discrimination of the models predicting PCSM for the
men with S-PCa was between 0.60 and 0.77, and for the men
with C-PCa it was between 0.51 and 0.68 (Fig. S4). The
calibration of the models in men with S-PCa was more
accurate than in men with C-PCa (Fig. S5). For the model by
Brockman et al. [10], the calibration slope was 0.08 for the
C-PCa and 0.84 for S-PCa group, for the model by Eggener
et al. [11] it was 0.29 for the C-PCa and 0.43 for the S-PCa
group, and for the model by Dell’Oglio et al. [9] it was 0.43
for the C-PCa and 0.92 for the S-PCa group. In addition, in
all models there was substantial miscalibration regarding the
probability of dying from PCa for both men with S-PCa and
those with C-PCa.
Discussion
In the present study, we performed an external validation of
models predicting BCR or PCSM. For the models predicting
BCR, we found that the difference in their discriminative
ability for the men with S-PCa and for those with C-PCa was
minimal, but was higher for men with S-PCa. The calibration
plots, however, showed a higher degree of overestimation of
the probability of experiencing BCR for the men with S-PCa.
This overestimation of experiencing BCR is probably
attributable to differences between a population-based
screening setting as compared to a referral population, where
the ﬁrst leads to more low-risk patients [22,23]. In addition,
independent of setting, early diagnosis coincides with better
prognosis [23].
The models with the best calibration slope were those by
Cooperberg et al. [8] and Walz et al. [7] for predicting
BCR. These models are most suitable for clinical utility,
taking into account that the baseline hazard needs to be
modiﬁed. This is probably the result of regional differences.
Difference in discrimination between the development
cohort and the validation cohort are likely to reﬂect
differences in case mix if the parameter estimates are
correct [24].
Screening-detected
Patient selection
Prediction models for PCSM
Exclusion (n = 4):
Inclusion
(n = 123)
Inclusion
(n = 389)
Men who experienced BCR (n = 127)
Clinically detected
Men who experienced BCR (n = 398)
Exclusion (n = 9):
- Initial treated with watchful waiting (n = 4)
- Initial treated with watchful waiting (n = 5)
- Initial treated with hormonal therapy (n = 2)
- pTO (n = 2)
Fig. 2 Flowchart of the patient inclusion for the external validation of the models predicting prostate cancer-speciﬁc mortality (PCSM) following
biochemical recurrence (BCR) after radical prostatectomy.
© 2019 The Authors
BJU International Published by John Wiley & Sons Ltd on behalf of BJU International 639
External validation of recurrence and PCa mortality
Ta
b
le
3
Ba
se
lin
e
c
h
a
ra
c
te
ris
tic
s
o
ft
h
e
p
a
tie
n
ts
w
h
o
e
xp
e
rie
n
c
e
d
b
io
c
h
e
m
ic
a
lr
e
c
u
rr
e
n
c
e
a
n
d
d
ie
d
w
ith
in
th
e
a
va
ila
b
le
fo
llo
w
-u
p
tim
e
O
ve
ra
ll
m
o
rt
a
lit
y
(n
=
22
6)
PC
SM
(n
=
92
)
O
th
e
r
c
a
us
e
o
f
d
e
a
th
(n
=
13
4)
O
ve
ra
ll
(n
=
22
6)
S-
PC
a
(n
=
53
C
-P
C
a
(n
=
17
3)
O
ve
ra
ll
(n
=
92
)
S-
PC
a
(n
=
24
)
C
-P
C
a
(n
=
68
)
O
ve
ra
ll
(n
=
13
4)
S-
PC
a
(n
=
29
)
C
-P
C
a
(n
=
10
5)
A
ge
at
su
rg
er
y,
ye
ar
s
M
ed
ia
n
(I
Q
R
)
65
.2
(6
1.
3–
68
.4
)
67
.0
(6
3.
0–
69
.0
)
64
.3
(6
0.
2–
68
.1
)
63
.0
(6
0.
4–
67
.6
)
66
.0
(6
2.
3–
68
.7
)
62
.8
(5
9.
2–
67
.2
)
65
.6
(6
2.
4–
68
.9
)
67
.7
(6
5.
3–
69
.2
)
65
.2
(6
1.
3–
68
.8
)
P
re
op
er
at
iv
e
P
SA
,
ng
/m
L
M
ed
ia
n
(I
Q
R
)
10
.5
(5
.8
–1
8.
7)
9.
6
(5
.0
–1
0.
9)
12
.4
(7
.4
–2
1.
4)
10
.4
(6
.0
–2
1.
6)
7.
4
(5
.8
–1
2.
3)
15
.3
(6
.2
–2
4.
5)
10
.5
(5
.7
–1
6.
5)
6.
3
(5
.0
–9
.2
)
12
.3
(7
.6
–1
8.
8)
P
at
ho
lo
gi
ca
l
st
ag
e,
n
(%
)
T
2A
–T
2B
29
(1
3)
6
(1
1)
23
(1
3)
6
(7
)
2
(8
)
4
(6
)
23
(1
7)
4
(1
4)
19
(1
8)
T
2C
31
(1
4)
20
(3
8)
11
(6
)
8
(9
)
6
(2
5)
2
(3
)
23
(1
7)
14
(4
8)
9
(9
)
T
3A
–T
3C
13
3
(5
9)
22
(4
2)
11
1
(6
4)
49
(5
3)
11
(4
6)
38
(5
6)
73
(5
4)
11
(3
8)
62
(5
9)
T
4A
–T
4B
33
(1
5)
5
(9
)
28
(1
6)
18
(2
0)
5
(2
1)
13
(1
9)
15
(1
1)
0
(0
)
15
(1
4)
P
at
ho
lo
gi
ca
l
G
le
as
on
sc
or
e,
n
(%
)
≤3
+
3
23
(1
0)
10
(1
9)
13
(8
)
4
(4
)
2
(8
)
2
(3
)
19
(1
4)
8
(2
8)
11
(1
0)
3
+
4
45
(2
0)
16
(3
0)
29
(1
7)
19
(2
1)
5
(2
1)
14
(2
1)
26
(1
9)
11
(3
8)
15
(1
4)
4
+
3
26
(1
2)
10
(1
9)
16
(9
)
15
(1
6)
6
(2
5)
9
(1
3)
11
(8
)
4
(1
4)
7
(7
)
≥4
+
4
28
(1
2)
13
(2
5)
15
(9
)
17
(1
8)
12
(5
0)
5
(7
)
12
(9
)
2
(7
)
10
(1
0)
U
nk
no
w
n
10
4
(4
6)
4
(8
)
10
0
(5
8)
38
(4
1)
0
(0
)
38
(5
6)
66
(4
9)
4
(1
4)
62
(5
9)
E
xt
ra
pr
os
ta
ti
c
ex
te
ns
io
n,
n
(%
)
N
on
e
12
2
(5
4)
9
(1
7)
11
3
(6
5)
55
(6
0)
6
(2
5)
49
(7
2)
67
(5
0)
3
(1
0)
64
(6
1)
In
te
rn
al
16
(7
)
14
(2
6)
2
(1
)
3
(3
)
3
(1
3)
0
(0
)
13
(1
0)
11
(3
8)
2
(2
)
E
xt
er
na
l
76
(3
4)
24
(4
5)
52
(3
0)
31
(3
4)
13
(5
4)
18
(2
6)
45
(3
4)
11
(3
8)
34
(3
2)
U
nk
no
w
n
12
(5
)
6
(1
1)
6
(3
)
3
(3
)
2
(8
)
1
(1
)
9
(7
)
4
(1
4)
5
(5
)
Su
rg
ic
al
m
ar
gi
ns
,
n
(%
)
P
os
it
iv
e
12
5
(5
5)
29
(5
5)
96
(5
5)
59
(6
4)
13
(5
4)
46
(6
8)
66
(4
9)
16
(5
5)
50
(4
8)
N
eg
at
iv
e
37
(1
6)
24
(4
5)
13
(8
)
15
(1
6)
11
(4
6)
4
(6
)
22
(1
6)
13
(4
5)
9
(9
)
U
nk
no
w
n
64
(2
8)
0
(0
)
64
(3
7)
18
(2
0)
0
(0
)
18
(2
6)
0
(0
)
0
(0
)
0
(0
)
Se
m
in
al
ve
si
cl
e
in
va
si
on
,
n
(%
)
P
os
it
iv
e
81
(3
6)
12
(2
3)
69
(4
0)
50
(5
4)
9
(3
8)
41
(6
0)
31
(2
3)
3
(1
0)
28
(2
7)
N
eg
at
iv
e
14
1
(6
2)
41
(7
7)
10
0
(5
8)
42
(4
6)
15
(6
3)
27
(4
0)
99
(7
4)
26
(9
0)
73
(7
0)
U
nk
no
w
n
4
(2
)
0
(0
)
4
(2
)
0
(0
)
0
(0
)
0
(0
)
4
(3
)
0
(0
)
4
(4
)
N
od
al
st
ag
e,
n
(%
)
N
X
4
(2
)
4
(8
)
0
(0
)
3
(3
)
3
(1
3)
0
(0
)
1
(1
)
1
(3
)
0
(0
)
N
0
18
9
(8
4)
47
(8
9)
14
2
(8
2)
73
(7
9)
19
(7
9)
54
(7
9)
11
6
(8
7)
28
(9
7)
88
(8
4)
N
1
31
(1
4)
2
(4
)
29
(1
7)
16
(1
7)
2
(8
)
14
(2
1)
15
(1
1)
0
(0
)
15
(1
4)
U
nk
no
w
n
2
(1
)
0
(0
)
2
(1
)
0
(0
)
0
(0
)
0
(0
)
2
(1
)
0
(0
)
2
(2
)
Fo
llo
w
-u
p
ti
m
e
af
te
r
R
P
,
ye
ar
s
M
ed
ia
n
(I
Q
R
)
9.
9
(6
.4
–1
3.
6)
10
.5
(6
.0
–1
4.
1)
9.
8
(6
.5
–1
3.
3)
8.
7
(6
.1
–1
1.
4)
7.
2
(4
.9
–1
1.
8)
8.
9
(6
.3
–1
1.
2)
11
.0
(6
.5
–1
4.
3)
13
.0
(9
.7
–1
4.
6)
9.
8
(6
.4
–1
4.
0)
B
C
R
,
bi
oc
he
m
ic
al
re
cu
rr
en
ce
;
C
-P
C
a,
cl
in
ic
al
ly
de
te
ct
ed
pr
os
ta
te
ca
nc
er
;
IQ
R
,
in
te
rq
ua
rt
ile
ra
ng
e;
PC
SM
,
pr
os
ta
te
ca
nc
er
-s
pe
ci
ﬁ
c
m
or
ta
lit
y;
R
P,
ra
di
ca
l
pr
os
ta
te
ct
om
y;
S-
P
C
a,
sc
re
en
in
g-
de
te
ct
ed
pr
os
ta
te
ca
nc
er
.
640
© 2019 The Authors
BJU International Published by John Wiley & Sons Ltd on behalf of BJU International
Remmers et al.
Discrimination will decrease if the case mix of the validation
cohort is homogeneous with the development cohort (e.g.
patient inclusion is based on stringent criteria). To elaborate,
the IQR of the preoperative PSA level in the model of
Brockman et al. [10] was 5.6–13.4 ng/mL, which is closer to
the PSA level of men with S-PCa (i.e. 5.1–17.5 ng/mL) as
compared to those with C-PCa (i.e. 6.9–19.9 ng/mL). In
addition, the calibration of the models predicting PCSM for
C-PCa and S-PCa was far from optimal, but slightly better
for the latter. It must be noted that the available follow-up
data for the development of the models of Brockman et al.
[10] and Eggener et al. [11] might not have been sufﬁcient to
provide reliable predictions on 15-year PCSM: the median
(IQR) follow-up of patients in the cohort described by
Brockman et al. [10] was 7 (4.0–10.8) years and in the cohort
described by Eggener et al. [11] it was only 4.7 (2.0–7.8)
years.
Some of the prediction models used in the present study have
been externally validated previously. For example, Lughezzani
et al. [25] validated the CAPRA prediction model of
Cooperberg et al. [8], and Tanaka et al. [26] validated the
prediction model of the September 2013 MSKCC nomogram.
Their results are in line with our study; however, the
difference between these external validations and the present
one is that we also included men with PCa detected purely
on the basis of an elevated PSA level and this way we clearly
show that differences in setting can affect the performance of
a prediction model.
The present external validation study is not without potential
limitations. The event rate for PCSM was limited as, within
the available follow-up, only 92 men with BCR (18%) died
from PCa after RP. In addition, there was no central review
of the RP specimen. Nevertheless, this reﬂects clinical practice
and it is unlikely that this would have affected the results. In
addition, in the present study we could not identify the best
performing model as the models differed in endpoints with
regard to timeline of predictions for both BCR and PCSM;
for BCR predictions were made for 2 and 5 years, and for
PCSM predictions were made for 5 and 15 years.
The strength of the present study is that the cause of death
of the men who participated in the ERSPC Rotterdam was
evaluated by a dedicated Cause of Death Committee. This
committee collected the complete medical record to obtain
information about metastases and progression, and whether
progressive metastatic disease caused death was decided by
means of a ﬂow chart. Without sufﬁcient information to
establish a cause of death, information was linked to
Statistics Netherlands to analyse death certiﬁcates. By using
a Cause of Death Committee, we could standardize the
cause of death of the men who participated in the ERSPC
Rotterdam study. The cause of death of the men who
participated in the Erasmus Medical Centre prostate cancer
study database were evaluated based on chart review by
experienced urologists.
Van den Broeck et al. [27] performed a recent meta-analysis
of men with curative treatment for PCa and who experienced
BCR in order to determine whether BCR was associated with
oncological outcomes and to identify prognostic factors for
oncological outcomes after BCR. They identiﬁed that, for men
primarily treated with RP, a PSA doubling time of > 1 year
and a pathological Gleason score < 8 indicated low risk for
distant metastasis, PCSM and overall mortality. A PSA
doubling time of ≤1 year or a pathological Gleason score ≥8
indicated high risk.
From a clinical perspective, our results have important
implications. While physicians and also patients are
encouraged to use the information from the prediction model
in their shared decision-making process, they should also
acknowledge the potential limitations of a prediction model
and when choosing a certain prediction model they should
consider discrepancies between their clinical setting and the
setting in which the model was developed.
In conclusion, we performed an external validation of models
predicting either BCR or PCSM after RP in a PSA-based
screening setting and a more clinical setting, including patients
after referral. Prediction models for BCR after RP showed good
discrimination and reasonable calibration in both settings;
however, when using predictions related to PCSM after RP,
prudence in their use and recalibration is advised given their
very limited performance in this external validation.
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